ClinicalTrials.gg
CompletedNCT02281747Updated Nov 6, 2026

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

An observational study in Rheumatoid Arthritis and Ankylosing Spondylitis, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Completed at 1 site in United States. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Observational

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
521,292
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Arthritis, Rheumatoid by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Enrollment
Largest of 11
521,292 · median 250
Started
2014
the only one that year
Observational
12 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Arthritis, Rheumatoid by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), this one has the largest enrollment of the 11 observational ones that give a count, is the only one that started in 2014, is one of 12 observational ones, and was the 18th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 19 studies in Arthritis, Rheumatoid by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Arthritis, Rheumatoid by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), or all of them as a file.
02

Study summary

Background:

- Orthopedic procedures are common in the United States. These include joint replacement and spine surgeries. Researchers want to study data about these procedures over time. They want to see if treatment has gotten better. They also want to find ways to change the care that people get before and after they have these procedures. These changes may lower the risk of problems people can have during and after treatment. They may also improve people s results.

Objectives:

- To study a series of questions about surgery, medicine, treatments, and outcomes for orthopedic procedures.

Eligibility:

- Data from the U.S. Centers for Medicare and Medicaid Services from 1999 to 2015.

Design:

  • Researchers will look at data for people ages 20-100.
  • No new participants will be used in this study.
  • The study will last 6 years.
Read the detailed description

Major orthopedic procedures, including total joint replacement and spine surgeries, are among the most common procedures in the population. Learning about how often these surgeries are performed can give indications of whether the treatment of arthritis and other musculoskeletal conditions has been improving over time. Learning about the complications associated with these surgeries can give indications about ways to alter the care of patients before and after surgeries that may decrease the risk of complications and improve patient outcomes. We will analyze Medicare and Medicaid data from 1999 to 2015 to examine a series of questions, including whether the use of joint replacement surgery has changed over time among patients with rheumatoid arthritis and ankylosing spondylitis, to see if rheumatoid arthritis medications are associated with some types of surgical complications, to see if anticoagulation medication after joint replacement is associated with the risk of complications, to see if regional differences in surgery rates can be explained by differences in patient characteristics, and to determine the surgical treatment for hip fractures that is associated with the fewest long-term complications. From the Framingham Heart Study Cohort, we will study the changes in the incidence of hip fractures and the risk factors for osteoporosis over time.

03

Conditions studied

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis

Keywords

  • Biologic Therapy
  • Rheumatoid Arthritis
  • Arthroplasty
  • Natural History
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Medicare (1999 to 2015) and Medicaid (1999 to 2015) beneficiaries

Eligibility criteria

  • Subjects will be either Medicare or Medicaid beneficiaries with available claims from 1999 to 2015. For projects requiring detailed medication information, inclusion will be limited to those with Part D claims from 2006 to 2015. Eligibility for each project will be based on claims for the appropriate disease (e.g. RA) or procedure (e.g. hip arthroplasty).

Medicare beneficiaries will be excluded (or censored) if they do not have both Part A and Part B coverage, or enrolled in Medicare Advantage plans (Part C), as detailed claims for these beneficiaries are not available. We will also exclude dual-eligible (Medicare and Medicaid recipients) as these subjects have distinct clinical conditions (e.g. blindness) that distinguishes them from most Medicare beneficiaries. There will be no exclusions based on gender, race, ethnicity, or cognitive impairment.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
521,292 participants (actual)

Groups and cohorts

  • affected with arthritis

    arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis

  • unaffected with arthritis

    in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritis status by clinically relevant subgroups.

06

What researchers measure

Primary outcomes

  1. Complications

    Complications

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — undecided yet

No publications or documents are linked to this record.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2014 to primary completion in Nov 2026, 144 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion May 2029 → Nov 2026 and completion May 2029 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 4, 2014
StartActual
Oct 24, 2014
Primary completionActual
Nov 4, 2026was May 2029
CompletionActual
Nov 4, 2026was May 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
May 30, 2029→Nov 4, 2026 (actual)
Nov 6, 2026
Study completion
May 31, 2029→Nov 4, 2026 (actual)
Nov 6, 2026
Show all 5 updates
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion May 30, 2029→Nov 4, 2026 (now actual)
    Study completion May 31, 2029→Nov 4, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 27, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 8, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 2, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02281747
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Oct 24, 2014
Primary completion
Nov 4, 2026
Completion
Nov 4, 2026
Last update
Nov 6, 2026

Study contacts

Robert A Colbert, M.D.
principal investigator · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion